Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.20
-2.19 (-26.10%)
At close: Nov 13, 2026, 4:00 PM EST
6.10
-0.10 (-1.61%)
After-hours: Nov 13, 2026, 7:55 PM EST

Candel Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.130.13
Revenue Growth
----0%0%
Gross Profit
-----20.22-14.47
Operating Income
-81.76-48.18-33.33-38-34.72-25.73
Net Income
-99.14-38.18-55.18-37.94-18.79-36.12
Earnings Per Share
-1.47-0.72-1.74-1.31-0.65-1.91
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
203.12119.73102.6535.4170.0682.64
Total Debt
49.7749.0313.4722.7622.80.56
Net Cash (Debt)
153.3570.789.1812.6547.2682.08
Net Cash Growth
92.27%-20.73%604.95%-73.23%-42.43%140.66%
Net Cash Per Share
2.281.332.820.441.644.35

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-68.91-38.31-27.02-34.24-31.42-22.22
Capital Expenditures
-1.29-0.59-0.02-0.46-1.3-1.84
Free Cash Flow
-70.2-38.9-27.04-34.7-32.72-24.05
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
-----27777.60%-20580.80%
Pretax Margin
-----15035.20%-28899.20%
Profit Margin
-----15035.20%-28899.20%
FCF Margin
-----26172.80%-19242.40%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
----413.761794.84